Literature DB >> 17574749

Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors.

You-yong Tian1, Cui-Ju Tang, Jia-ning Wang, Yuan Feng, Xiao-wu Chen, Lan Wang, Xian Qiao, Sheng-gang Sun.   

Abstract

Vascular endothelial growth factor (VEGF) is a specific angiogenic peptide, which has been identified to play a critical role in neurodegeneration, and has beneficial effects on neurons. In this study, we investigated whether neurodegeneration in a rat model of Parkinson disease could be prevented by VEGF gene transfer mediated by adeno-associated virus (AAV) vectors. Our results demonstrated that a single injection of a VEGF-expressing AAV vector into striatum improved the rotational behavior of rat Parkinson disease models, and promoted the survival of dopaminergic neurons and fibers. Meanwhile, AAV-VEGF injection significantly increased the reactive astrocytes and the levels of glial cell line-derived neurotrophic factor in striatum, but did not induce extra angiogenesis and remarkable disorder of blood-brain barrier. We thus conclude that intrastriatal delivery of VEGF gene mediated by AAV has favorable effects on the dopaminergic neurons in a rat Parkinson disease model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574749     DOI: 10.1016/j.neulet.2007.05.033

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

1.  Evolution of the VEGF-regulated vascular network from a neural guidance system.

Authors:  Sreenivasan Ponnambalam; Mario Alberghina
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

2.  Hyaluronic acid-laminin hydrogels increase neural stem cell transplant retention and migratory response to SDF-1α.

Authors:  C P Addington; S Dharmawaj; J M Heffernan; R W Sirianni; S E Stabenfeldt
Journal:  Matrix Biol       Date:  2016-09-17       Impact factor: 11.583

3.  Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.

Authors:  Stuart M Ellison; Antonio Trabalza; Veronica Tisato; Evangelos Pazarentzos; Shirley Lee; Vasiliki Papadaki; Despoina Goniotaki; Sarah Morgan; Nazanin Mirzaei; Nicholas D Mazarakis
Journal:  Mol Ther       Date:  2013-06-25       Impact factor: 11.454

Review 4.  VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration.

Authors:  Peter Carmeliet; Carmen Ruiz de Almodovar; Ruiz de Almodovar Carmen
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

Review 5.  Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.

Authors:  Xiaoyun Xu; Jinsha Huang; Jie Li; Ling Liu; Chao Han; Yan Shen; Guoxin Zhang; Haiyang Jiang; Zhicheng Lin; Nian Xiong; Tao Wang
Journal:  Cell Prolif       Date:  2016-01-08       Impact factor: 6.831

Review 6.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

Review 7.  VEGF as a potential target for therapeutic intervention in depression.

Authors:  Jennifer L Warner-Schmidt; Ronald S Duman
Journal:  Curr Opin Pharmacol       Date:  2007-12-03       Impact factor: 5.547

Review 8.  The blood-brain barrier in neurodegenerative disease: a rhetorical perspective.

Authors:  Paul M Carvey; Bill Hendey; Angela J Monahan
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

9.  Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease.

Authors:  Torsten Falk; Shiling Zhang; Scott J Sherman
Journal:  Mol Neurodegener       Date:  2009-12-10       Impact factor: 14.195

10.  Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.

Authors:  Nian Xiong; Jinsha Huang; Zhentao Zhang; Zhaowen Zhang; Jing Xiong; Xingyuan Liu; Min Jia; Fang Wang; Chunnuan Chen; Xuebing Cao; Zhihou Liang; Shenggang Sun; Zhicheng Lin; Tao Wang
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.